YourChoice Therapeutics

YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

All edits by  Meredith Hanel 

Edits on 18 January, 2019
Meredith Hanel
Meredith Hanel approved a suggestion from Golden's AI on 18 January, 2019 8:09 pm
Edits made to:
Article (+14/-14 characters)
Article

YourChoice Therapeutics was one of the 2018 CITRIS Foundry Startups. One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motilitysperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

Meredith Hanel
Meredith Hanel approved a suggestion from Golden's AI on 18 January, 2019 8:09 pm
Edits made to:
Article (+5/-5 characters)
Article

YourChoice Therapeutics was one of the 2018 CITRIS Foundry Startups. One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

Meredith Hanel
Meredith Hanel edited on 18 January, 2019 8:09 pm
Edits made to:
Infobox (+2 properties)
Infobox
Meredith Hanel
Meredith Hanel edited on 18 January, 2019 7:29 pm
Edits made to:
Description (+238 characters)
Article (+653 characters)
People (+3 rows) (+6 cells) (+90 characters)
Further reading (+1 rows) (+3 cells) (+137 characters)
Categories (+1 topics)
Topic thumbnail

YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

Article

YourChoice Therapeutics was one of the 2018 CITRIS Foundry Startups. One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

People

Name
Role
Related Golden topics

Akash Bakshi

Co-Founder, CEO

Nadja Mannowetz

Co-Founder, CSO

POLINA LISHKO

Founder, Consultant

Further reading

Title
Author
Link
Type

Regulation of the sperm calcium channel CatSper by endogenous steroids and plant triterpenoids

Web

Categories
Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 18 January, 2019 6:59 pm
Edits made to:
Topic thumbnail

 YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.